CMV UL56 Target-Capture Assay for Sensitive Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests for human cytomegalovirus (CMV) are not sensitive and specific, requiring multiple tests and being limited to symptomatic individuals, which poses challenges in managing CMV infections, especially in pregnant women and immunocompromised patients.
Innovation Solution
The development of amplification oligomers, nucleic acids, and methods for detecting and quantifying CMV, including forward and reverse primers, promoter primers, probe oligomers, and target capture oligomers, which facilitate sensitive and specific detection and quantification of the CMV UL56 gene sequence using nucleic acid amplification techniques like PCR and isothermal transcription-mediated amplification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic tests are used for CMV detection, then testing can be performed, but sensitivity and specificity are insufficient requiring multiple tests
Solution Approach 1:
The patent combines multiple diagnostic functions into a single nucleic acid amplification test that simultaneously achieves high sensitivity and specificity for CMV detection. The method integrates target capture, amplification, and detection steps into one unified assay, eliminating the need for multiple separate tests while maintaining or improving diagnostic accuracy.
Solution Approach 2:
The diagnostic method is designed to be universally applicable for CMV detection with high sensitivity and specificity in a single test platform. The amplification oligomers and detection probes are engineered to work together in one assay system, providing multi-functional capability for both detection and quantification of CMV nucleic acid.
2Reliability
If current diagnostic tests are used for CMV detection, then testing can be performed, but multiple tests are required which increases time and resource consumption
Solution Approach 1:
The patent merges multiple diagnostic steps into a single integrated nucleic acid amplification test that achieves reliable CMV detection in one assay. By combining target capture, amplification, and detection functions, the method reduces the total testing time while maintaining high detection accuracy, eliminating the sequential execution of multiple separate tests.
Solution Approach 2:
The method incorporates preliminary target capture and enrichment steps that prepare the sample for amplification, allowing the main detection to proceed efficiently. This preliminary action ensures that only relevant CMV nucleic acid sequences are amplified and detected, reducing the time needed for subsequent steps while maintaining high reliability.
3Measurement precision
If current diagnostic tests are used for CMV detection, then testing can be performed, but they are limited to symptomatic individuals
Solution Approach 1:
The patent employs parameter changes in the form of highly sensitive nucleic acid amplification conditions and optimized probe designs that enable detection of low levels of CMV nucleic acid. This increased sensitivity allows the test to detect asymptomatic infections where viral loads are below the threshold of conventional tests, expanding applicability beyond symptomatic individuals.
Solution Approach 2:
The diagnostic method is designed with universal applicability for both symptomatic and asymptomatic CMV detection. The high sensitivity of the nucleic acid amplification approach allows it to function effectively across different clinical scenarios, making it adaptable for screening asymptomatic populations while maintaining diagnostic accuracy for symptomatic cases.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid, direct, and specific detection and quantification of CMV, allowing for effective management of CMV infections in transplant recipients and pregnant women, with the potential to detect low viral loads accurately.
Implementation Method 1
The amplification oligomers include forward primers, reverse primers, promoter primers (e.g., T7 primers), non-promoter primers (e.g., NT7 primers), helper oligomers and displacer oligomers
Implementation Method 2
The methods involve the amplification of viral nucleic acid to detect the CMV target sequence in the sample
Implementation Method 3
Further described are probe oligomers and target capture oligomers (TCO) that facilitate detection of amplified sequence
Implementation Method 4
target capture oligomers (TCO) that facilitate detection of amplified sequence and isolation of CMV nucleotide sequence from a sample
Data Source
AI summary
Oligomer nucleotides, compositions, methods, kits, and uses are provided for detecting or quantifying a Human Cytomegalovirus virus 1 (CMV (human herpesvirus 5, HHV5) nucleic acid, e.g., using nucleic acid amplification and hybridization assays. Multiphase amplification of a CMV target sequence is also described. The oligomer nucleotides, compositions, methods, kits, and uses can be used to amplify and/or detect the UL56 gene of CMV.